Navigation Links
Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
Date:10/21/2013

New York, New York (PRWEB) October 21, 2013

The nationwide law firm of Bernstein Liebhard LLP (http://www.consumerinjurylawyers.com) is investigating Risperdal lawsuits on behalf of young men and boys who developed a condition called gynecomastia, or male breast growth, allegedly due to their use of Risperdal. According to court documents, hundreds of product liability lawsuits are now moving forward in a consolidated proceeding underway in Philadelphia Common Pleas Court in Pennsylvania, all of which allege an association between Risperdal and male breast growth. (In Re: Risperdal Litigation, No. 00296)

“Risperdal lawsuits pending in the Pennsylvania proceeding accuse Johnson & Johnson of concealing the alleged link between Risperdal and male breast growth. We are interested in hearing from anyone who developed this condition while using Risperdal,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.

Risperdal and Male Breast Growth
According to its prescribing information, Risperdal is an atypical antipsychotic drug used to treat adult and adolescent schizophrenia, as well as bipolar disorder in adults and children ages 10-to-17. Risperdal is also approved to treat irritability in children (5-to-16 years of age) with autistic disorder.* Research also indicates that off- label use of Risperdal to treat ADHD is also on the rise.**

According to research published in 2006 in the Journal of Clinical Psychopharmacology, Risperdal may cause the body to produce excessive amounts of a hormone called prolactin, which is known to stimulate breast growth and milk production in women. Excessive levels of prolactin were associated with gynecomastia in boys and the development of lactation in girls, according to the study authors. ***

According to the Mayo Clinic, gynecomastia is the swelling of the breast tissue in boys or men. Symptoms of Gynecomastia may include:

  •     Swelling
  •     Pain
  •     Tenderness
  •     Nipple discharge in one or both breasts

In the most severe cases, liposuction or mastectomy may be required to treat gynecomastia.****

In October 2012, Bloomberg.com reported that Johnson & Johnson had agreed to settle five
Risperdal lawsuits involving gynecomastia allegations. The cases were to be the first tried in the Risperdal litigation underway in Philadelphia. Those settlements came just months after the company agreed to pay more than $2 million to settle charges brought by the U.S. Department of Justice that it marketed Risperdal for unapproved uses. The company has also reached similar settlements with prosecutors in a number of states, Bloomberg.com said.****

Individuals who were treated with Risperdal are urged to contact Bernstein Liebhard LLP for a free legal consultation if they developed gynecomastia or male breast growth while taking this drug. To learn more about filing a Risperdal lawsuit, please contact the Firm by calling 800-511-5092.

*accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
**health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
***journals.lww.com/psychopharmacology/Abstract/2006/04000/Risperidone_induced_Symptomatic.10.aspx, Journal of Clinical Psychopharmacology, April 2006
****Bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 10, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-male-breast/prweb11252916.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Transvaginal Mesh Lawsuit Update: New Study Concerning Use of Vaginal Mesh in Prolapse Procedures, Bernstein Liebhard LLP Reports
2. Cell Phone Radiation Lawsuit Update: ICEMS Position Paper Supports Italian Supreme Court Ruling on Cell Phones and Brain Tumors, Bernstein Liebhard LLP Reports
3. Cell Phones and Brain Cancer: American Academy of Pediatrics Endorses Cell Phone Right to Know Act, Bernstein Liebhard LLP Reports
4. Pradaxa Side Effect Warning: Pradaxa Label to Warn Blood-Thinner Shouldn’t be Used in People with Mechanical Heart Valves, Bernstein Liebhard LLP Reports
5. New Metal-on-Metal Hip Implant Study Emphasizes Importance of Patients’ Symptoms in Evaluating the Need for Hip Replacement Revisions, Bernstein Liebhard LLP Reports
6. Pradaxa Lawsuits Being Investigated by Bernstein Liebhard LLP, as Next Conference in Federal Pradaxa Litigation Set for January 10th
7. Propecia Lawsuits Being Investigated by Bernstein Liebhard LLP, as Propecia Litigation Pending in New Jersey Superior Court Continues to Move Forward
8. DePuy ASR Hip Recall, Transvaginal Mesh Lawsuit Updates: Bernstein Liebhard LLP Looks Forward to Start of First Bellwether Trials in New Year
9. Stryker Hip Recall Lawsuits Being Evaluated by Bernstein Liebhard LLP, Following Recall of Stryker Rejuvenate and ABG II Modular Neck Stems
10. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
11. 176 Pradaxa Lawsuits Now Pending in Federal Litigation, Discovery Well Underway, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, households ... mail from USA Medical Prescription Assistance Program. They are customized to reflect the ... package will include a ready-to-use, state-themed card and, in the near future, material ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in Motion Coalition ... an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and data collection. ... 1, 2016. , Sarcopenia is defined as a combination of low muscle mass and ...
(Date:4/28/2016)... ... April 28, 2016 , ... North Hollywood dentist , Dr. Hamid ... is essential when it comes to dental accidents or critical dental problems. These issues ... losing a tooth. Toothaches, knocked-out teeth, chipped teeth, and many other issues can lead ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... an invitation to those affected by a health insurance co-operative bankruptcy to ... proprietary process, individuals can receive over 1,500 FDA-approved prescription medications from over ...
(Date:4/28/2016)... , ... April 28, 2016 , ... For many, a diet is only as good ... if it does not look good. In addition, an individual cannot deny the importance of ... , The team, therefore, has worked to create a product range that could entice people ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
Breaking Medicine Technology: